Antonio Gotto

Antonio Gotto, MD, DPhil

Full Member, Research Institute
Houston Methodist
Professor of Medicine, Provost for Medical Affairs & Dean Emeritus, Weill Cornell Medical College


Biography

Dr. Antonio M. Gotto is the Stephen and Suzanne Weiss Dean of Weill Cornell Medical College in New York, New York, where he is also Professor of Medicine. In addition, Dr. Gotto is Provost for Medical Affairs of Cornell University. He joined Houston Methodist Research Institute in 2011. Previously, at Baylor College of Medicine in Houston, Texas, he was the Bob and Vivian Smith Professor and Chairman of the Department of Medicine, Scientific Director of the DeBakey Heart Center, and the JS Abercrombie Chair for Atherosclerosis and Lipoprotein Research. He also served as Chief of the Internal Medicine Service at The Methodist Hospital in Houston. Dr. Gotto's postgraduate work included doctoral studies at Oxford University in England as a Rhodes Scholar, and residency training at the Massachusetts General Hospital in Boston, Massachusetts.

As a lifelong supporter of educational efforts aimed at cardiovascular risk reduction, Dr. Gotto has been National President of the American Heart Association and President of the International Atherosclerosis Society. He is a member of the Institute of Medicine and the American Academy of Arts and Sciences and a recipient of many honors, including the Gold Heart Award from the American Heart Association, the 2000 Distinguished Alumnus award from Vanderbilt University and the Vanderbilt University School of Medicine, honorary doctoral degrees from the University of Bologna and Abilene Christian University, honorary professorships from the University of Buenos Aires and Francisco Marroquin University (Guatemala), and the Order of the Lion from the Republic of Finland. Dr. Gotto was the 2004 recipient of the International Okamoto Award from the Japan Vascular Disease Research Foundation. In 2004 Dr. Gotto was also named Honorary Member of the Society for Progress in Internal Medicine (Ludwig Heilmeyer Society) in Germany. In 2010, he received the Maurice R. Greenberg Distinguished Service Award, the highest honor bestowed by New York-Presbyterian/Weill Cornell on members of the medical staff.

Dr. Gotto speaks nationally and internationally on cardiovascular disease and has contributed more than 500 scholarly articles and books to the medical literature. In addition, he is coauthor of a series of books that explain the origins and treatment of cardiovascular disease to the general public.

Description of Research

In the field of atherosclerosis, his basic science research interests include clinical disorders of lipid transport and the structure, metabolism, and function of lipoproteins and apolipoproteins. He and his associates were the first to achieve complete synthesis of a plasma apolipoprotein (apo C-I); they also determined the complete cDNA and amino acid sequence of apo B-100, one of the largest proteins ever sequenced and a key protein in atherosclerosis. In addition, Dr. Gotto has played a leading role in several landmark clinical trials demonstrating that cholesterol-lowering drug treatment can reduce the risk of heart disease.

Areas Of Expertise

Lipoproteins and apolipoproteins Atherosclerosis Lipid metabolism Statins
Education & Training

D Phil, University of Oxford
MD, Vanderbilt University
Publications

The pathophysiology of excess plasma-free cholesterol
Gillard, BK, Rosales, C, Gotto, AM & Pownall, HJ 2023, , Current opinion in lipidology, vol. 34, no. 6, PMID: 37732779, pp. 278-286. https://doi.org/10.1097/MOL.0000000000000899, https://doi.org/10.1097/MOL.0000000000000899

The pathophysiology of excess plasma-free cholesterol
Gillard, BK, Rosales, C, Gotto, AM & Pownall, HJ 2023, , Current opinion in lipidology, vol. 34, no. 6, pp. 278-286. https://doi.org/10.1097/MOL.0000000000000899

Serum Opacity Factor Normalizes Erythrocyte Morphology in Scarb1-/- Mice in an HDL-Free Cholesterol-Dependent Way.
Wang, Z, Yelamanchili, D, Liu, J, Gotto, AM, Rosales, C, Gillard, BK & Pownall, HJ 2023, , Journal of lipid research, vol. 64, no. 11, 100456, pp. 100456. https://doi.org/10.1016/j.jlr.2023.100456, https://doi.org/10.1016/J.JLR.2023.100456

Bempedoic acid lowers high-sensitivity C-reactive protein and low-density lipoprotein cholesterol: Analysis of pooled data from four phase 3 clinical trials
Stroes, ESG, Bays, HE, Banach, M, Catapano, AL, Duell, PB, Laufs, U, Mancini, GBJ, Ray, KK, Sasiela, WJ, Zhang, Y & Gotto, AM 2023, , Atherosclerosis, vol. 373, pp. 1-9. https://doi.org/10.1016/j.atherosclerosis.2023.03.020

Normalization of Erythrocyte Morphology in Scarb1-/- Mice by Bacterial Serum Opacity Factor is HDL-Free Cholesterol Dependent
Rosales, C, Wang, Z, Yelamanchili, D, Gotto, A, Gillard, BK & Pownall, HJ 2023, , ASBMB Deuel Conference on Lipids, Dana Point, CA, 3/7/23 - 3/10/23.

Serum opacity factor rescues fertility among female Scarb1-/- mice by reducing HDL-free cholesterol bioavailability
Rosales, C, Yelamanchili, D, Gillard, BK, Liu, J, Gotto, AM & Pownall, HJ 2023, , Journal of lipid research, vol. 64, no. 2, 100327, pp. 100327. https://doi.org/10.1016/j.jlr.2022.100327

The pathophysiology of excess plasma-free cholesterol.
Gillard, BK, Rosales, C, Gotto, A & Pownall, HJ 2023, , Current opinion in lipidology, vol. 34, PMID: 37732779, pp. 278-286.

Serum Opacity Factor Normalizes Erythrocyte Morphology in Scarb1-/- Mice in an HDL-Free Cholesterol-Dependent Way.
Wang, Z, Yelamanchili, D, Liu, J, Gotto, A, Rosales, C, Gillard, BK & Pownall, HJ 2023, , Journal of lipid research.

Serum opacity factor normalizes erythrocyte morphology in Scarb1-/- mice in an HDL-free cholesterol-dependent way
Wang, Z, Yelamanchili, D, Liu, J, Gotto, AM, Rosales, C, Gillard, BK & Pownall, HJ 2023, , Journal of lipid research, vol. 64, no. 11, 100456. https://doi.org/10.1016/J.JLR.2023.100456

Serum Opacity Factor Rescues Fertility among Female Scarb1-/- Mice by Reducing HDL-Free Cholesterol Bioavailability
Rosales, C, Yelamanchili, D, Gillard, BK, Liu, J, Gotto, A & Pownall, HJ 2022, , Journal of lipid research, vol. 64, no. 2, PMID: 36596339.

Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
Cholesterol Treatment Trialists Collaboration 2022, , The Lancet, vol. 400, no. 10355, pp. 832-845. https://doi.org/10.1016/S0140-6736(22)01545-8

Excess HDL Free Cholesterol Bioavailability Drives Free Cholesterol Accretion into Macrophages and Erythrocytes in SCRAB1-/- mice
Gillard, BK, Wang, Z, Liu, J, Yelamanchili, D, Gotto, A, Rosales, C & Pownall, HJ 2022, , AHA Vascular Discovery: From Genes to Medicine 2022 Scientific Sessions, Seattle, United States, 5/12/22 - 5/14/22.

Serum Opacity Factor Normalizes Dysfunctionnal High Density Lipoproteins in SRBI-/- Female Mice and Rescues Fertility.
Yelamanchili, D, Gillard, BK, Pownall, HJ, Gotto, A & Rosales, C 2022, , AHA Vascular Discovery: From Genes to Medicine 2022 Scientific Sessions, Seattle, United States, 5/12/22 - 5/14/22.

Excess HDL Free Cholesterol Bioavailability Drives Free Cholesterol Accretion into Macrophages and Erythrocytes in SCRAB1-/- mice.
Gillard, BK, Wang, Z, Liu, J, Yelamanchili, D, Gotto, A, Rosales, C & Pownall, HJ 2022, , ASBMB Deuel Conference on Lipids, Monterey, United States, 3/1/22 - 3/4/22.

Serum Opacity Factor Normalizes Dysfunctionnal High Density Lipoproteins in SRBI-/- Female Mice and Rescues Fertility.
Yelamanchili, D, Gillard, BK, Pownall, HJ, Gotto, A & Rosales, C 2022, , ASBMB Deuel Conference on Lipids, Monterey, United States, 3/1/22 - 3/4/22.

Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: A post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials
Leiter, LA, Banach, M, Catapano, AL, Duell, PB, Gotto, AM, Laufs, U, Mancini, GBJ, Ray, KK, Hanselman, JC, Ye, Z & Bays, HE 2022, , Diabetes, Obesity and Metabolism, vol. 24, no. 5, pp. 868-880. https://doi.org/10.1111/dom.14645

Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials
Laufs, U, Ballantyne, CM, Banach, M, Bays, H, Catapano, AL, Duell, PB, Goldberg, AC, Gotto, AM, Leiter, LA, Ray, KK, Bloedon, LAT, MacDougall, D, Zhang, Y & Mancini, GBJ 2022, , Journal of Clinical Lipidology, vol. 16, no. 3, pp. 286-297. https://doi.org/10.1016/j.jacl.2022.03.001

Atherosclerosis risk classification with computed tomography angiography: A radiologic-pathologic validation study
Buckler, AJ, Gotto, AM, Rajeev, A, Nicolaou, A, Sakamoto, A, St Pierre, S, Phillips, M, Virmani, R & Villines, TC 2023, , Atherosclerosis, vol. 366, pp. 42-48. https://doi.org/10.1016/j.atherosclerosis.2022.11.013

Serum Opacity Factor Rescues Fertility among Female Scarb1-/- Mice by Reducing HDL-Free Cholesterol Bioavailability.
Rosales, C, Yelamanchili, D, Gillard, BK, Liu, J, Gotto, A & Pownall, HJ 2022, , Journal of lipid research, vol. 64, no. 2, PMID: 36596339.

In memoriam of Rodolfo Paoletti a tribute to a friend
Gotto, AM 2021, , Journal of Clinical Lipidology, vol. 15, no. 5, pp. 627-628. https://doi.org/10.1016/j.jacl.2021.07.006